Torrent Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹13,980cr+21.4% on FY25
EBITDA: ₹4,559cr+22.5% on FY25
Net profit: ₹2,138cr+11.9% on FY25
EPS: ₹63.92+13.2% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	17,400	13,980	11,516	10,728	9,620	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	−52.0	−94.0	23.0	58.0	45.0
	17,348	13,886	11,539	10,786	9,665
	2,177	1,758	1,520	1,657	1,480
	2,023	1,619	1,531	1,184	1,089
	1.0	11.0	−275	−155	166
	3,227	2,671	2,203	1,984	1,678
	886	385	252	354	333
	1,916	1,119	795	808	707
	4,198	3,362	2,816	2,690	2,365
	14,428	10,925	8,842	8,522	7,818
	5,774	4,559	3,721	3,368	2,842
	3,858	3,440	2,926	2,560	2,135
Profit
	2,920	2,961	2,697	2,264	1,847
	−107	−89.0	−24.0	88.0	0.0
	2,813	2,872	2,673	2,352	1,847
	962	844	619	462	374
	−248	−110	143	234	228
	714	734	762	696	602
	2,099	2,138	1,911	1,656	1,245
	2,099	2,138	1,911	1,656	1,245
	−33.0	−180	−93.0	17.0	−137
	2,066	1,958	1,818	1,673	1,108
	2,124	2,163	1,911	1,656	1,245
	−25.0	−25.0	0.0	0.0	0.0
Per share
	₹59.20	₹63.92	₹56.47	₹48.94	₹36.79
	₹59.20	₹63.92	₹56.47	₹48.94	₹36.79
Other comprehensive income — detail
	−33.0	−180	−93.0	—	—
	−17.0	0.0	−28.0	−13.0	9.0
	−4.0	0.0	−6.0	—	—
	—	—	—	−4.0	5.0
	−12.0	−228	−78.0	46.0	−179
	8.0	−48.0	−7.0	—	—
	—	—	—	20.0	−38.0
	2,090	1,982	1,818	1,673	1,108
	−24.0	−24.0	0.0	0.0	0.0
Per share — as-filed variants
	₹59.20	₹63.92	₹56.47	₹48.94	₹36.79
	₹59.20	₹63.92	₹56.47	₹48.94	₹36.79
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	13,199	10,592	8,740	8,042	6,885
	75.9%	75.8%	75.9%	75.0%	71.6%
Adjusted (ex-exceptional items) — derived
	2,920	2,961	2,697	2,264	1,847
	−107	−89.0	−24.0	88.0	0.0
	2,179	2,204	1,928	1,594	1,245
	₹61.45	₹65.90	₹56.98	₹47.11	₹36.79

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TORNTPHARM₹4,557.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA JBCHEPHARM MANKIND ZYDUSLIFE DIVISLAB MAXHEALTH DRREDDY CIPLAMcap ₹1.54L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	9,620.0	10,728.0	11,516.0	13,980.0	17,400.0
Other Income	45.0	58.0	23.0	-94.0	-52.0
Total Income	9,665.0	10,786.0	11,539.0	13,886.0	17,348.0
Expenses
+ Cost of Materials Consumed	1,480.0	1,657.0	1,520.0	1,758.0	2,177.0
+ Purchases of Stock-in-Trade	1,089.0	1,184.0	1,531.0	1,619.0	2,023.0
+ Changes in Inventories	166.0	-155.0	-275.0	11.0	1.0
+ Employee Benefit Expense	1,678.0	1,984.0	2,203.0	2,671.0	3,227.0
+ Finance Costs	333.0	354.0	252.0	385.0	886.0
+ Depreciation & Amortisation	707.0	808.0	795.0	1,119.0	1,916.0
+ Other Expenses	2,365.0	2,690.0	2,816.0	3,362.0	4,198.0
Total Expenses	7,818.0	8,522.0	8,842.0	10,925.0	14,428.0
EBITDA	2,842.0	3,368.0	3,721.0	4,559.0	5,774.0
EBIT	2,135.0	2,560.0	2,926.0	3,440.0	3,858.0
Profit
PBT before Exceptional Items	1,847.0	2,264.0	2,697.0	2,961.0	2,920.0
+ Exceptional Items	0.0	88.0	-24.0	-89.0	-107.0
Pretax Income	1,847.0	2,352.0	2,673.0	2,872.0	2,813.0
+ Current Tax	374.0	462.0	619.0	844.0	962.0
+ Deferred Tax	228.0	234.0	143.0	-110.0	-248.0
Tax Expense	602.0	696.0	762.0	734.0	714.0
Net Income	1,245.0	1,656.0	1,911.0	2,138.0	2,099.0
+ Net Income — Continuing Ops	1,245.0	1,656.0	1,911.0	2,138.0	2,099.0
+ Other Comprehensive Income	-137.0	17.0	-93.0	-180.0	-33.0
Total Comprehensive Income	1,108.0	1,673.0	1,818.0	1,958.0	2,066.0
Net Income to Common	1,245.0	1,656.0	1,911.0	2,163.0	2,124.0
Minority Interest	0.0	0.0	0.0	-25.0	-25.0
Per Share
Basic EPS	36.79	48.94	56.47	63.92	59.20
Diluted EPS	36.79	48.94	56.47	63.92	59.20
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-93.0	-180.0	-33.0
+ Items NOT to be Reclassified to P&L	9.0	-13.0	-28.0	0.0	-17.0
+ Tax on Items NOT to be Reclassified	—	—	-6.0	0.0	-4.0
+ Tax on Items NOT to be Reclassified — alt tag	5.0	-4.0	—	—	—
+ Items to be Reclassified to P&L	-179.0	46.0	-78.0	-228.0	-12.0
+ Tax on Items to be Reclassified	—	—	-7.0	-48.0	8.0
+ Tax on Items to be Reclassified — alt tag	-38.0	20.0	—	—	—
Comprehensive Income — Owners of Parent	1,108.0	1,673.0	1,818.0	1,982.0	2,090.0
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	-24.0	-24.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	36.79	48.94	56.47	63.92	59.20
Diluted EPS — Continuing Operations	36.79	48.94	56.47	63.92	59.20
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	6,885.0	8,042.0	8,740.0	10,592.0	13,199.0
Gross Margin %	71.57	74.96	75.89	75.77	75.86
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,847.0	2,264.0	2,697.0	2,961.0	2,920.0
− Exceptional Items (reconciliation)	0.0	88.0	-24.0	-89.0	-107.0
Net Income Adj (tax-effected)	1,245.0	1,594.0	1,928.2	2,204.3	2,178.8
EPS Adj	36.79	47.11	56.98	65.90	61.45
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00
Filed Debt Equity	—	—	0.40	—	—
Filed Dscr	—	—	3.87	—	—
Filed Iscr	—	—	12.43	—	—
Paid Up Equity Capital	169.2	169.2	169.2	169.2	190.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.